Close Menu

Breaking News

The firm said that it will use proceeds from the sale to purchase or repay other notes or loans, including up to $300 million in outstanding senior notes.

The Finnish company also announced that it has received CE-IVD marking for its Aiforia Clinical pathology image analysis platform.

The study, sponsored by the US Centers for Disease Control and Prevention, focused on men who have sex with men and members of their social networks.

PTC Therapeutics is developing a gene therapy for the rare genetic disease AADC deficiency, which impacts the production of two key neurotransmitters.

BD said TRC Capital Investment had made an unsolicited offer to BD shareholders to buy up to 500,000 shares of BD's stock at a price below the current market value.

The firm said it has received several "conditional, non-binding indications of interest" from potential merger or acquisition partners.

The Tucson, Arizona-based company previously raised $20 million through a public offering of its shares and a purchase deal with certain investors.

The test will now be considered medically reasonable and necessary for patients over 45 with moderately elevated levels of prostate-specific antigen. 

The company incurred a net loss of $5.2 million, or $.10 per share, slightly exceeding the $.09 per share loss that analysts had predicted on average.

News items for the week of Nov. 11, 2019. 

The firm will use funds from the round, led by the Midlands Engine Investment Fund, to develop its optical point-of-care diagnostic testing platform.

The partners will evaluate circulating tumor cell-based biomarker panels as potential new tests for use on Ikonisys' Ikoniscope fluorescence microscopy system.

Cardinal Health will offer the device as a standalone product to hospitals and as part of a customizable kit to address blood culture contamination. 

The company said it intends to use net proceeds from the offering to support development and commercialization for its DetermaVu and Razor assays.

The company signed a distribution agreement in Japan for its Idylla products and also initiated a listing of €150 million in unsecured convertible bonds.

JP Morgan noted that it sees potential for new management to "reset the bar" and as such thinks the "worst is in the rearview for Qiagen."

The genetic testing firm is offering approximately 2.3 million shares at $11.25 per share and plans to use the funds for general corporate purposes.

The German molecular diagnostics firm is preparing for its merger with US-based OpGen, which is slated to close in the first quarter of next year.

The firm said that in a first phase of the contract it will focus on further development of its fever test that analyzes immune system gene expression patterns.

The new name better reflects its business model combining MDx testing with the drug discovery and development services business it acquired from Cancer Genetics.

The San Diego-based company said that the number of commercial samples received during the quarter grew 66 percent year over year.

This report contains a quantitative, evidence-based scoring framework to help guide the evaluation of constitutional CNVs across clinical labs.

The company said it will use the funds to accelerate expansion of its MeMed BV test, which distinguishes between bacterial and viral infections.

The company said it will use the proceeds to increase commercialization of its PreTRM test, a blood biomarker test to determine the risk of premature delivery.

The company posted $1.3 million in revenues with OVA1 test sales up 82 percent to 3,602 and revenue per test down 8 percent to $345.

Pages